Patient Characteristics from a Fexuprazan Study for Stroke and GERD, 2023-2025

18 patients with acute ischemic stroke and gastroesophageal reflux disease (GERD) receiving antithrombotic therapy were treated with fexuprazan and followed for 12 weeks. The dataset, created by Minyoul Baik and last updated in April 2026, contains participant characteristics from this prospective single-arm study conducted between June 2023 and March 2025. The mean age was 65.6 years and 50.0% of participants were male.

Use Cases

• Analyze baseline patient demographics based on age and gender distribution mentioned in the results.
• Study the relationship between GERD symptom scores (GerdQ) and clinical outcomes in a specific patient population.
• Examine safety profiles of potassium-competitive acid blockers in patients receiving antithrombotic therapy.
• Benchmark characteristics for small, single-arm clinical studies in neurology and gastroenterology.

Strengths

• Includes specific clinical metrics such as mean GerdQ scores at baseline (8.8) and 12 weeks (6.6).
• Contains detailed patient inclusion criteria: acute ischemic stroke, GERD (GerdQ score ≥8), and antithrombotic therapy.
• Data is from a prospective study with a defined follow-up period of 12 weeks.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The study had a small sample size of 18 patients and lacked a control group, as noted in the conclusions.

Provenance

Source

Minyoul Baik via figshare

Collection Method

Prospective, single-center, single-arm clinical study.

Time Range

June 2023 to March 2025 (study period).

Freshness

Last updated 2026-04-03 17:53:13; freshness should be verified.

Geography

Single-center study; specific location is unknown.